Women have an increased risk for major adverse cardiovascular events at lower levels of coronary plaque burden.

Phase 3 PEACE-2 data indicates that the addition of cabazitaxel to ADT plus RT did not improve clinical PFS in very high risk prostate cancer.

HealthDay News — Major adverse cardiovascular events emerge at a lower coronary plaque burden (PB) in women than men, according to a study published in Circulation.

A 20-year follow-up of older adults in the ACTIVE randomized trial linked to Medicare claims found that speed of processing ...

GLP-1 receptor agonists were not associated with recurrence or progression in well differentiated thyroid cancer, supporting ...

Cancer after cardiac surgery was linked to shorter long-term survival in a retrospective study. Read more to find out more.

Adjuvant therapy with Imfinzi (durvalumab) and Imjudo (tremelimumab-actl) in patients with resected renal cell carcinoma was ...

Perioperative enfortumab vedotin plus pembrolizumab and surgery lead to significantly better outcomes among patients with ...

MDT associated with improved progression-free, radiographic progression-free, castration resistance-free survival.

Pivotal study shows no clear benefit for the common endoscopic procedure in this patient group. Experts say the new data ...

A custom NGS panel covering 27 IARC carcinogenic HPV genotypes enabled detection of ccfHPV DNA across treatment strata and ...

Children with obstructive sleep apnea are nearly twice as likely to contract influenza or COVID-19, according to a recent ...